Expert Opinion on Therapeutic Patents

Papers
(The TQCC of Expert Opinion on Therapeutic Patents is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
FAK inhibitors in cancer, a patent review – an update on progress41
Recent developments of agents targeting Vibrio cholerae : patents and literature data41
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)39
Malaria transmission blocking compounds: a patent review36
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)36
Update on mGlu4 modulator patents: 2017 to present35
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities34
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)29
The role of patent analysis in target selection29
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)28
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review28
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present28
Caspase inhibitors: a review on recently patented compounds (2016–2023)27
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)25
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)24
An updated patent review of AKT inhibitors (2020 – present)22
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)22
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
A patent review of MAPK inhibitors (2018 – present)22
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202321
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201321
EOTP-2025-ST-0028.R1Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)20
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)20
Antiprotozoal drugs: challenges and opportunities20
Inhibition of GTPase KRAS G12D : a review of patent literature20
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)19
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review19
PDE1 inhibitors: a review of the recent patent literature (2008-present)18
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)18
Small-molecule RNA ligands: a patent review (2018–2024)18
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)16
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)16
Antimalarial drugs: what’s new in the patents?15
An updated patent review of MALT1 inhibitors (2021–present)15
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature15
An updated patent review on PD-1/PD-L1 antagonists (2022-present)15
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)15
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)15
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders15
A patent review of IDH1 inhibitors (2018-present)15
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)14
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)14
A patent and literature review of CDK12 inhibitors14
Biofilm and bacterial membrane vesicles: recent advances14
Dopamine D3 receptor ligands: a patent review (2014–2020)14
An updated patent review on drugs for the treatment of tuberculosis (2018-present)13
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)13
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review13
An updated patent review of EZH2 inhibitors (2024–present)13
Are patents important indicators of innovation for Chagas disease treatment?13
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs12
A patent review of NLRP3 inhibitors to treat autoimmune diseases12
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)12
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience12
Biomedical applications of prokaryotic carbonic anhydrases: an update12
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)11
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents11
The patent review of the biological activity of tropane containing compounds11
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa11
An updated patent review of TRPA1 antagonists (2020 – present)11
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)10
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)10
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 1-patent granted10
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)10
A patent review of BRD4 inhibitors (2020–present)10
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity10
Correction10
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)10
0.085815906524658